Evidence map›Paper›PMID 42733562›Full record

ArticleMolecular therapy. Oncology2026

Targeting LKB1-inactivated lung cancers with a stapled peptide inhibitor of the CRTC-CREB pathway.

Xin Zhou, Gregory H Bird, Mu Yu, Jian-Liang Li, Xzaviar K Solone, Michael C Chung, Juan Guan, Loren D Walensky, Lizi Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xin ZhouDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Gregory H BirdDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Mu YuDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Jian-Liang LiIntegrative Bioinformatics, National Institute of Environmental Health Sciences, Durham, NC 27709, USA.
Xzaviar K SoloneDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.
Michael C ChungCollege of Pharmacy, University of Texas, Austin, TX 78712, USA.
Juan GuanCollege of Pharmacy, University of Texas, Austin, TX 78712, USA.
Loren D WalenskyDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lizi WuDepartment of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.

Funding

Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human CancerR35CA197583 · NCI · DANA-FARBER CANCER INST · PI Loren David Walensky · 2015 to 2026
$12.5M
Signaling and Targeting of CRTC1-MAML2 Fusion Oncoprotein in Salivary Gland TumorR01DE023641 · NIDCR · UNIVERSITY OF FLORIDA · PI Lizi Wu · 2014 to 2026
$3.3M
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human CancerR50CA211399 · NCI · DANA-FARBER CANCER INST · PI Gregory Howard Bird · 2016 to 2026
$3.2M
Mechanisms of Assembly and Functional Regulation in Non-canonical Biomolecular CondensatesR35GM146877 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Juan Guan · 2022 to 2026
$2.0M
Modulation of Therapeutic Response in Lung Cancer by Tumor Suppressor LKB1R01CA304148 · NCI · UNIVERSITY OF FLORIDA · PI Lizi Wu · 2026 to 2026
$487k
NCI NIH HHS R01 CA304148NCI NIH HHS R35 CA197583NCI NIH HHS R50 CA211399NIDCR NIH HHS R01 DE023641NIGMS NIH HHS R35 GM146877
6 · The paper itself

Abstract

Non-small cell lung cancers (NSCLCs) with inactivation of the tumor suppressor LKB1 are common and respond poorly to current therapies. We previously identified aberrant activation of the CRTC-CREB transcriptional pathway as a key driver of malignancy in LKB1-deficient lung cancer. In this study, we developed stabilized α-helical peptides, termed stabilized alpha helices of the CREB binding domain (SAH-CBDs), which were designed to disrupt the CRTC-CREB protein-protein interaction. SAH-CBD peptides adopt a stable, bioactive α-helical conformation, bind directly to CREB, and effectively block CRTC-CREB complex formation

Indexed as

CREBCRTC coactivatorsLKB1non-small cell lung cancerstapled peptides

Identifiers

PMID42733562
PMCPMC13571231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.